biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Hobberson Jan 15, 2015 10:46am

123 Views

Post# 23322913

RE:Getting through the BBB

A little more on the previous post:

From Rick's Science Page:

AveXxis and Genzyme are both developing gene therapy approaches in which a harmless virus is genetically modified to express the missing SMN1 gene. This virus is unique in that it can be injected intravenously and still penetrate the blood brain barrier and enter into the critical motor neuron cells. In addition to entering motor neurons and other cells in the central nervous system the virus can enter into other tissues such as the liver, heart, kidneys, etc. This is a very promising approach that has produced stunning results in the survival of the mouse model of SMA type 1, giving them a nearly normal lifespan.

https://onegenefromperfect.com/?page_id=88

Bullboard Posts

Canadian artificial intelligence ETFs